Tolani F. Olonisakin

Tolani F. Olonisakin

Auto-generated profile, based on publicly available information

Tolani F. Olonisakin

Division of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMarco Mascarella
Marco Mascarella
TOTolani F. Olonisakin
Tolani F. Olonisakin
PRPurva Rumde
Purva Rumde
VVVarun Vendra
Varun Vendra
MNMelonie A. Nance
Melonie A. Nance
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Purpose: Neoadjuvant targeted therapy provides a brief, preoperative window of opportunity that can be exploited to individualize cancer care based on treatment response. We investigated whether response to neoadjuvant therapy during the preoperative window confers survival benefit in patients with operable head and neck squamous cell carcinoma (HNSCC). Patients and Methods: A pooled analysis of treatment-naïve patients with operable HNSCC enrolled in one of three clinical trials from 2009 to 2020 (NCT00779389, NCT01218048, NCT02473731). Neoadjuvant regimens consisted of EGFR inhibitors (n = 83) or anti-ErbB3 antibody therapy (n = 9) within 28 days of surgery. Clinical to pathologic stage migration was compared with disease-free survival (DFS) and overall survival (OS) while adjusting for confounding factors using multivariable Cox regression. Circulating tumor markers validated in other solid tumor models were analyzed. Results: 92 of 118 patients were analyzed; all patients underwent surgery following neoadjuvant therapy. Clinical to pathologic downstaging was more frequent in patients undergoing neoadjuvant targeted therapy compared with control cohort (P = 0.048). Patients with pathologic downstage migration had the highest OS [89.5%; 95% confidence interval (CI), 75.7–100] compared with those with no stage change (58%; 95% CI, 46.2–69.8) or upstage (40%; 95% CI, 9.6–70.4; P = 0.003). Downstage migration remained a positive prognostic factor for OS (HR, 0.22; 95% CI, 0.05–0.90) while adjusting for measured confounders. Downstage migration correlated with decreased circulating tumor markers, SOX17 and TAC1 (P = 0.0078). Conclusions: Brief neoadjuvant therapy achieved pathologic downstaging in a subset of patients and was associated with significantly better DFS and OS as well as decreased circulating methylated SOX17 and TAC1.

3 March 2022 in American Journal of Rhinology & Allergy
Verified
Journal Article
Closed access
TOTolani F. Olonisakin
Tolani F. Olonisakin
JMJohn A. Moore
John A. Moore
SBStephanie Barel
Stephanie Barel
BUBliss Uribe
Bliss Uribe
DPDana M. Parker
Dana M. Parker
SLStella E. Lee
Stella E. Lee
Background: Fractional exhaled nitric oxide (FeNO) is a cost-effective, noninvasive point-of-care test that has proven valuable in identifying patients with lower airway inflammation and predicting the likelihood of responsiveness to inhaled corticosteroid therapy in asthma. The utility of FeNO in upper airway disease, specifically in CRS, remains to be determined. Objective: The goal of this study was to test whether FeNO could serve as a noninvasive marker of sinonasal mucosal inflammation in CRS patients. Methods: FeNO was obtained using a nitric oxide analyzer (NIOX VERO) as well as nasal mucus, the 22-item Sinonasal Outcome Test (SNOT-22), University of Pennsylvania Smell Identification Test (UPSIT), and Lund-Kennedy endoscopic scores concurrently in 112 CRS patients. Nasal mucus was analyzed for cytokine expression using solid-phase sandwich ELISA. Linear regression with Spearman correlation coefficient was used to determine strength of relationship between variables. Results: CRS patients showed elevated FeNO levels with asthma (47.12 ± 5.21 ppb) or without asthma (43.24 ± 9.810 ppb). Elevated FeNO levels correlated with sinonasal mucosal inflammation, as determined by increased levels of CCL26 and TNFα in nasal mucus obtained from CRS patients. Furthermore, elevated FeNO levels selectively correlated with worsened SNOT-22 nasal symptoms (P = 0.03) and Lund-Kennedy endoscopic scores (P = 0.007), but did not correlate with UPSIT scores. Conclusions: FeNO levels correlated with increased sinonasal mucosal inflammation and symptom severity in CRS regardless of asthma status. FeNO measurements may serve as a quick and noninvasive marker in evaluating CRS patients.

29 April 2022 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
JMJymirah Morris
Jymirah Morris
TOTolani F. Olonisakin
Tolani F. Olonisakin
JMJohn A. Moore
John A. Moore
BPBaDoi Phan
BaDoi Phan
DPDana M. Parker
Dana M. Parker
SLStella E. Lee
Stella E. Lee

1 March 2018 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Open access
TOTolani F. Olonisakin
Tolani F. Olonisakin
JLJanet S. Lee
Janet S. Lee

25 November 2025
Verified
Other
Open access
MMMarco Mascarella
Marco Mascarella
TOTolani F. Olonisakin
Tolani F. Olonisakin
PRPurva Rumde
Purva Rumde
VVVarun Vendra
Varun Vendra
MNMelonie A. Nance
Melonie A. Nance
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Patient characteristics of control group

25 November 2025
Verified
Other
Open access
MMMarco Mascarella
Marco Mascarella
TOTolani F. Olonisakin
Tolani F. Olonisakin
PRPurva Rumde
Purva Rumde
VVVarun Vendra
Varun Vendra
MNMelonie A. Nance
Melonie A. Nance
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
CONSORT diagram of patients included neoadjuvant targeted therapy trials